Anti-obesity drugs: A review about their effects and safety

Research output: Contribution to journalReview articlepeer-review

495 Scopus citations

Abstract

The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years, numerous drugs have been approved for the treatment of obesity; however, most of them have been withdrawn from the market because of their adverse effects. In fact, amphetamine, rimonabant and sibutramine licenses have been withdrawn due to an increased risk of psychiatric disorders and non-fatal myocardial infarction or stroke. Even if orlistat is not as effective as other drugs in reducing body weight, orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and positive effects on diabetic control. Hopefully, more effective and better tolerated anti-obesity drugs will be developed through an improved understanding of the multiple mechanisms and complex physiological systems targeting appetite.

Original languageEnglish
Pages (from-to)13-25
Number of pages13
JournalDiabetes and Metabolism Journal
Volume36
Issue number1
DOIs
StatePublished - Feb 2012
Externally publishedYes

Keywords

  • Anti-obesity agents
  • Obesity
  • Safety

Fingerprint

Dive into the research topics of 'Anti-obesity drugs: A review about their effects and safety'. Together they form a unique fingerprint.

Cite this